Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,097.11 +93.65 (+9.33%)

Streaming Delayed Price Updated: 10:41 AM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth

January 02, 2026

As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...

Via MarketMinute

Topics Artificial Intelligence Economy

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

Via MarketMinute

Topics Economy Intellectual Property World Trade

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

S&P 500 Tests Critical Support Levels as 2026 Kicks Off Under Technical Pressure

January 02, 2026

The S&P 500 (INDEXSP:.INX) entered the new year on a tenuous footing, grappling with a rare four-session losing streak that capped off an otherwise stellar 2025. After finishing the final trading day...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today ↗

January 02, 2026

Via Benzinga

Alphabet’s Golden Year: Inside the 2025 Rally and the Future of the AI Giant

January 02, 2026

As we enter 2026, the narrative surrounding the world’s most dominant information gateway has shifted from one of existential threat to unprecedented strength. Alphabet Inc. (NASDAQ: GOOGL / GOOG) has...

Via PredictStreet

Topics Artificial Intelligence Initial Public Offering

2 S&P 500 Stocks with Impressive Fundamentals and 1 We Avoid

January 01, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Via StockStory

Topics Stocks

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

Via TokenRing AI

Topics Artificial Intelligence

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

January 01, 2026

The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...

Via TokenRing AI

Topics Artificial Intelligence

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Via MarketMinute

Topics Intellectual Property

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

Navigating the Neutral Rate: Wall Street's 2026 Outlook Forecasts Growth Amidst AI Maturity

January 01, 2026

As the opening bell prepares to ring for the first time in 2026, the American investor finds themselves at a unique crossroads of technological maturation and economic normalization. Following a robust...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗

January 01, 2026

These two companies have very different risk-reward profiles.

Via The Motley Fool

Topics Artificial Intelligence

Where Will Pfizer Be in 5 Years? ↗

December 31, 2025

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

Via The Motley Fool

Topics Intellectual Property

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026 ↗

December 31, 2025

Via MarketBeat

So Long, Warren. Buffett Leaves Astonishing Gains As He Steps Down As CEO. ↗

December 31, 2025

Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.

Via Investor's Business Daily

Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine

December 31, 2025

The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI...

Via TokenRing AI

Topics Artificial Intelligence Bonds

The 2026 Earnings Gauntlet: Can Corporate Profits Justify Wall Street's High-Wire Act?

December 31, 2025

As the clock strikes midnight on December 31, 2025, the U.S. stock market stands at a historic crossroads. The S&P 500 has closed the year at record highs, fueled by a relentless surge in artificial...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value

December 31, 2025

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Could This Potential Move Boost Eli Lilly's Prospects? ↗

December 31, 2025

The stock already looks unstoppable, and this move won't hurt its momentum.

Via The Motley Fool

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗

December 31, 2025

Via MarketBeat

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Via Stocktwits

Topics Economy Government

The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier

December 30, 2025

As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the...

Via TokenRing AI

Topics Artificial Intelligence

S&P 500 Hovers at the Flatline: A Masterclass in Market Resilience or the Quiet Before a 2026 Storm?

December 30, 2025

As the sun sets on 2025, the S&P 500 is holding its breath. In a trading session characterized by thin holiday volume and a notable absence of institutional conviction, the benchmark index spent much...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Why Novo Nordisk Stock Dropped on Monday ↗

December 30, 2025

The cost of Wegovy is about to decrease significantly in a populous overseas market.

Via The Motley Fool

Topics Intellectual Property

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Topics ETFs Economy World Trade

The Trillion-Dollar Shuffle: How Year-End Institutional Rebalancing is Fueling Late-December Volatility

December 30, 2025

As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High? ↗

December 30, 2025

History is clear about what investors should do heading into the new year.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.